A BRISTOL BASED PHARMACEUTICAL COMPANY IS REPORTING A STRONG CASH FLOW FROM OPERATIONS IN THE SECOND QUARTER OF THE YEAR. BRISTOL TENNESSEE BASED KING PHARMACEUTICALS ANNOUNCED TOTAL REVENUE OF 445 MILLION COMPARED TO 397 MILLION THE SAME PERIOD LAST YEAR. THE COMPANY REPORTED NET INCOME OF 38 MILLION DURING THE SECOND QUARTER OF THIS YEAR COMPATED TO 41 MILLION THE PRIOR YEAR. ALSO, KING BELIEVES ITS CLOSER TO AN APPROVAL OF EMBEDA, REMOXY AND ACUROX WHICH WOULD BE A FIRST IN CLASS OPIAD FORMULATION DESIGNED TO DETER MISUSE AND ABUSE OF DRUGS.